Telavancin’s “Complete Response” Letter Calls For Pregnancy-Focused REMS

Theravance is the last of the three sponsors from a marathon advisory committee review of antibiotics for cSSSI to get an action letter; as the only one with a positive vote, it’s the only one that doesn’t need further trials.